These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 25034619)

  • 21. Background to the ADI/TDI/PTWI.
    Herrman JL; Younes M
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S109-13. PubMed ID: 10597623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of biomarkers in human pharmacology (Phase I) studies.
    Cohen AF; Burggraaf J; van Gerven JM; Moerland M; Groeneveld GJ
    Annu Rev Pharmacol Toxicol; 2015; 55():55-74. PubMed ID: 25292425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug dosing in elderly patients with chronic kidney disease.
    Lassiter J; Bennett WM; Olyaei AJ
    Clin Geriatr Med; 2013 Aug; 29(3):657-705. PubMed ID: 23849014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Approaches to Japanese dose evaluation in global drug development: factors that generate different dosages between Japan and the United States.
    Nakashima K; Narukawa M; Takeuchi M
    Clin Pharmacol Ther; 2011 Dec; 90(6):836-43. PubMed ID: 22048222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors associated with spontaneous reporting of adverse drug reactions in Japan.
    Yamada T; Watanabe Y; Kusama M; Sugiyama Y; Ono S
    Pharmacoepidemiol Drug Saf; 2013 May; 22(5):468-76. PubMed ID: 23172714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Editorial: Recent Advances in Developmental Drug Disposition.
    Collier AC
    Drug Metab Lett; 2015; 9(2):64. PubMed ID: 26517862
    [No Abstract]   [Full Text] [Related]  

  • 28. Hospital readmission for adverse drug reactions.
    Prescrire Int; 2015 Feb; 24(157):46. PubMed ID: 25802920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potentials and limitations of nonclinical safety assessment for predicting clinical adverse drug reactions: correlation analysis of 142 approved drugs in Japan.
    Tamaki C; Nagayama T; Hashiba M; Fujiyoshi M; Hizue M; Kodaira H; Nishida M; Suzuki K; Takashima Y; Ogino Y; Yasugi D; Yoneta Y; Hisada S; Ohkura T; Nakamura K
    J Toxicol Sci; 2013; 38(4):581-98. PubMed ID: 23824014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toward experimental assessment of receptor occupancy: TGN1412 revisited.
    Waibler Z; Sender LY; Kamp C; Müller-Berghaus J; Liedert B; Schneider CK; Löwer J; Kalinke U
    J Allergy Clin Immunol; 2008 Nov; 122(5):890-2. PubMed ID: 18805577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety Profile Based on Concordance of Nonclinical Toxicity and Clinical Adverse Drug Reactions for Blood Cancer Drugs Approved in Japan.
    Kubota S; Saito K; Ono S; Kodama Y
    Drugs R D; 2017 Mar; 17(1):133-143. PubMed ID: 27995532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of clinical risks by analysis of preclinical and clinical adverse events.
    Clark M
    J Biomed Inform; 2015 Apr; 54():167-73. PubMed ID: 25746390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Problems encountered in the pharmacovigilance of violence and aggression.
    Prescrire Int; 2014 Jun; 23(150):154. PubMed ID: 25121149
    [No Abstract]   [Full Text] [Related]  

  • 34. Rational use of medicines in older adults: Can we do better during clinical development?
    Saeed MA; Vlasakakis G; Della Pasqua O
    Clin Pharmacol Ther; 2015 May; 97(5):440-3. PubMed ID: 25676612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.
    Shah RR
    Xenobiotica; 1993 Nov; 23(11):1159-93. PubMed ID: 8310705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statistical concepts in the planning and evaluation of drug safety from clinical trials in drug development: issues of international harmonization.
    O'Neill RT
    Stat Med; 1995 May 15-30; 14(9-10):117-27. PubMed ID: 7569506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.
    Muller PY; Brennan FR
    Clin Pharmacol Ther; 2009 Mar; 85(3):247-58. PubMed ID: 19177065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative benefit-risk analysis for evaluating drug therapies.
    Kodell RL; Chen JJ
    J Biopharm Stat; 2013; 23(1):231-8. PubMed ID: 23331233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonclinical & clinical interface - extrapolation of nonclinical data to support Phase I clinical studies.
    Baldrick P; Reichl A
    Regul Toxicol Pharmacol; 2021 Apr; 121():104869. PubMed ID: 33482290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection.
    Saber H; Del Valle P; Ricks TK; Leighton JK
    Regul Toxicol Pharmacol; 2017 Nov; 90():144-152. PubMed ID: 28887049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.